PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number 10/568,941 February 21, 2006 Filing Date ANSMITTAL First Named Inventor FORM Michael Horstmann et al. Art Unit 1614 **Examiner Name** all correspondence after initial filing) Attorney Docket Number RO4150US (#90568) Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers of Appeals and Interferences Fee Attached Appeal Communication to TC Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a Proprietary Information Provisional Application After Final Power of Attorney, Revecation Status Letter Change of Correspondence Address Affidavits/declaration(s) Other Enclosure(s) (please Identify Terminal Disclaimer below): Extension of Time Request Post card Request for Refund Express Abandonment Request Transmittal ltr w/Power of Attorney & International Pre-CD, Number of CD(s) Information Disclosure Statement liminary Report on Patentability Landscape Table on CD Certified Copy of Priority Remarks Document(s) Please charge any additional fees or credit any overpayment Reply to Missing Parts/ to Deposit Account No. 08-2441. incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name D. Peter Hochberg Co., L.P.A. Signature Printed name Peter Hochberg Reg. No. Date 24,603 www 26,2007 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature Date Christine Kotran Typed or printed name

Under the Paperwork Reduction Act of 1995, no persons

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Michael Horstmann et al.

Serial No.:

10/568,941

Filed:

February 21, 2006 / Conf. No. 7611

Title:

TRANSDERMAL PHARMACEUTICAL PREPARATION

CONTAINING ACTIVE SUBSTANCE COMBINATIONS

FOR TREATING PARKINSON'S, DISEASE

Examiner:

Art Unit:

1614

Attorney File:

RO4150US (#90568)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL FOR POWER OF ATTORNEY AND INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

Sir:

Enclosed for entry on the records of the USPTO are a Power of Attorney duly executed by the inventors and an English translation of the International Preliminary Report on Patentability rendered on the parent International Application No. PCT/EP2004/009136. The IPRP was transmitted to the designated/elected Offices on July 20, 2006.

Respectfully submitted,

By:

D. Peter Hochberg Reg. No. 24,603

DPH/SM/ck Enc.

D. Peter Hochberg Co., L.P.A. 1940 E. 6th Street - 6TH Floor Cleveland, Ohio 44114 Phone: (216) 771-3800

Fax: (216) 771-3804

e-mail: DPHDOCKET@aol.com

Certificate of Mailing

I hereby certify that this document, and anything indicated as being attached or enclosed, is being deposited with the United States Postal Service as First Class mail in an envelope addressed: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on the date noted below.

Christine Kotran: Christine / Cobran

Date: //26/2007

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF TRANSMITTAL
OF COPIES OF TRANSLATION
OF THE INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY
(CHAPTER I OR CHAPTER II
OF THE PATENT COOPERATION TREATY)
(PCT Rules 44bis.3(c) and 72.2)

То:	
FLACCUS, Rolf-Die Bussardweg 10 50389 Wesseling	
ALLEMAGNE	2 6. JULI 2006
	FRIST:

Date of mailing (day/month/year)
20 July 2006 (20.07.2006)

Applicant's or agent's file reference LTS 2003/005 PCT

International application No. PCT/EP2004/009136

IMPORTANT NOTIFICATION

International filing date (day/month/year)
14 August 2004 (14.08.2004)

Applicant

LTS LOHMANN THERAPIE-SYSTEME AG et al

1.	Transmittal	of the	e translation	to	the applicant.
----	-------------	--------	---------------	----	----------------

The International Bureau transmits herewith a copy of the English translation of the international preliminary report on patentability (Chapter I).

The International Bureau transmits herewith a copy of the English translation of the international preliminary report on patentability (Chapter II).

2. Transmittal of the copy of the translation to the designated or elected Offices.

The International Bureau notifies the applicant that copies of that translation have been transmitted to the following designated or elected Offices requiring such translation:

KR

The following designated or elected Offices, having waived the requirement for such a transmittal at this time, will receive copies of that translation from the International Bureau only upon their request:

AE, AG, AL, AM, AP, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EA, EC, EE, EG, EP, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OA, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

3. Reminder regarding translation into (one of) the official language(s) of the elected Office(s).

The applicant is reminded that, where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability (Chapter II).

It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned within the applicable time limit (Rule 74.1). See Volume II of the PCT Applicant's Guide for further details.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

Agnes Wittmann-Regis

Facsimile No. +41 22 338 82 70

Facsimile No. +41 22 338 82 70

PATENT COOPERATION TREATY

Translation

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

1	nt's or agent's file reference 2003/005 PCT	FOR FURTHER	ACTION	See Form PCT/IPEA/416		
International application No. Interna		International filing d	ate (day/month/year)	Priority date (day/month/year)		
PCT	/EP2004/009136	14.08.200	14	20.08.2003		
Internati	onal Patent Classification (IPC) or n	ational classification and	IPC			
A61	K9/70					
1	Applicant LTS LOHMANN THERAPIE-SYSTEME AG					
1.	This report is the international pre- under Article 35 and transmitted to			nternational Preliminary Examining Authority		
2.	This REPORT consists of a total of	6	sheets, including	this cover sheet.		
3.	This report is also accompanied by	ANNEXES, comprising	:			
	a. (sent to the applicant as	nd to the International R	ureau) a total of	sheets, as follows:		
	a. (sent to the applicant and to the International Bureau) a total of sheets, as follows: sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).					
	sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.					
	b. (sent to the International	d Bureau only) a total of	(indicate type and number	of electronic carrier(s))		
	— , ,	,,		• •		
	, containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).					
4.	This report contains indications rela	ting to the following ite	ms:			
	Box No. I Basis of t	he report		•		
	Box No. II Priority					
	Box No. III Non-estal	lishment of opinion with	h regard to novelty, inventi	ve step and industrial applicability		
	Box No. IV Lack of u	nity of invention				
	DOX 110. 1	statement under Article and explanations support	• •	ty, inventive step or industrial applicability;		
	Box No. VI Certain de	ocuments cited				
. •	Box No. VII Certain de	fects in the international	application			
L	Box No. VIII Certain of	servations on the intern	ational application			
Date of s	Date of submission of the demand Date of completion of this report					
Name an	d mailing address of the IPEA/EP		Authorized officer			
Easter!	- N.		Malankara Ma			

International application No.
PCT/EP2004/009136

Во	x No. I		Basis of the report			
1.			to the language, this report is based on the internation der this item.	nal application in the language in	which it was filed, unless otherwise	
			eport is based on translations from the original langua is the language of a translation furnished for the purp		<u> </u>	
			international search (Rule 12.3 and 23.1(b))			
		H	publication of the international application (Rule 12.4))		
	*****		international preliminary examination (Rule 55.2 and/			
2.	rece	iving Oj report):	to the elements of the international application, this fice in response to an invitation under Article 14 are	report is based on (<i>repiacement s</i> e referred to in this report as "o	theets which have been furnished to the riginally filed" and are not annexed to	
		the int	ernational application as originally filed/furnished	•		
	M	the de	scription:			
		pages	1-15		as originally filed/furnished	
		pages*		received by this Authority on		
		pages*	·	received by this Authority on		
	\boxtimes	the cla	ims:			
		nos.			as originally filed/furnished	
		nos.*		as amended (together	r with any statement) under Article 19	
		nos.*	1-13	received by this Authority on	14.06.2005 with letter of 13.06.2005	
		nos.*		received by this Authority on		
		the dra	wings:			
		sheets			as originally filed/furnished	
		sheets'		received by this Authority on		
		sheets'		received by this Authority on		
		a segue	ence listing and/or any related table(s) – see Supplems	ental Box Relating to Sequence L	isting	
3		-	nendments have resulted in the cancellation of:			
٥.	_		, 2			
			he description, pages he claims, nos.		· · · · · · · · · · · · · · · · · · ·	
		$\overline{\Box}$				
			he sequence listing (specify):			
4.			any table(s) related to sequence listing (specify):		Date de la laction de la constant de	
7.	Ш	they ha	port has been established as if (some of) the amendate been considered to go beyond the disclosure as file.	ed, as indicated in the Supplemen	tal Box (Rule 70.2(c)).	
		Ц,	he description, pages			
		□ '	he claims, nos.			
		<u> </u>	he drawings, sheets/figs			
		the sequence listing (specify):				
*	If ite	m 4 app	lies, some or all of those sheets may be marked "supe			

International application No.
PCT/EP2004/009136

Во	x No. II	Priority					
1.	This r	eport has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the sted:					
	copy of the earlier application whose priority has been claimed (Rule 66.7(a)).						
		translation of the earlier application whose priority has been claimed (Rule 66.7(b)).					
2.	This r	eport has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid					
	(Rule	64.1). Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.					
3.	Additional o	observations, if necessary:					
		·					
	-						
	•						
•							

International application No.
PCT/EP2004/009136

Box N	No. V	Reasoned stateme citations and expla	nt under An anations su	rticle 35(2) with regard to novelty, inventive step or industrial applicability; opporting such statement	
1.	Statement				
	Novelty ((N)	Claims	1-13	YES
			Claims		_ NO
	Inventive	step (IS)	Claims		YES
	•		Claims	1-13	NO
	Industrial	applicability (IA)	Claims	1-13	YES
i			Claims		NO
				· · · · · · · · · · · · · · · · · · ·	-

2. Citations and explanations (Rule 70.7)

Novelty

1. Claims 1-13 appear to meet the requirements of PCT Article 33(2) for novelty, since none of the prior art citations discloses the subject matter of these claims (transdermal medicinal preparation containing said combination of active substances).

Inventive step

2. The present invention can therefore be considered to address the problem of providing "alternative combination therapies for treating Parkinson's disease".

The solution consists in **transdermal** medicinal preparations.

Transdermal medicinal preparations which contain dopamine agonists are already known from the prior art (cf. D7, D8 and D11).

The subject matter of claims 1 and 2 differs from documents D7, D8 and D11 in that the claimed medicinal preparation contains additional active substances. This combination of particular active substances in a

International application No.
PCT/EP2004/009136

Box No. V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

transdermal medicinal form is unknown from the prior art.

These active substances have already been successfully administered transdermally as a combination therapy, but not in the claimed combinations (cf. D2: MAO-B inhibitor and anticholinergic agents; D3: MAO-B inhibitor and dopamine agonist; D4: MAO-B inhibitor and NMDA agonist).

In view of the explanations in the prior art, a person skilled in the art would consider it a conventional procedure to combine a dopamine agonist or L-dopa with other anti-parkinsonian agents, in order to achieve the same effect.

This type of transdermal combination, as defined in the claims, can only be considered inventive if the particular combination of active substances shows unexpected effects or properties in relation to the prior art. However, the application does not indicate such effects or properties.

Consequently, the application cannot be recognised to involve an inventive step (PCT Article 33(3)).

International application No.
PCT/EP2004/009136

Box No. VII Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

PCT Article 19

The new claim 7 is not allowed because the specific combination of sympathicomimetic agents with the active substances mentioned in the preceding claims was not explicitly disclosed in the original application.